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REPLY
We thank Dr. Massel for his interest in our study (1), and though
we agree with some of his points, there is one major flaw with his
reasoning: The optimal percutaneous transluminal coronary angio-
plasty (PTCA) group was defined in the study as having near
perfect angiographic results, whereas the routine stent group as
defined included all patients, whether or not an optimal (or even
successful!) result was obtained. Most pertinently, 100% of patients
in the optimal PTCA group achieved Thrombolysis In Myocardial
Infarction (TIMI) flow grade 3 (by definition), compared to only
95.7% of patients in the routine stent group (p  0.0001), clearly
explaining the weak trends toward increased mortality Massel
notes. In light of this unfair playing field, it is particularly
noteworthy that the benefits of stents in reducing restenosis and
infarct artery reocclusion are still strongly apparent. As we stated in
the Limitations section of our report, our data are hypothesis
generating only; an adequately powered randomized trial of stent-
ing versus no stenting in patients achieving optimal PTCA results
is required to definitely address this issue. Such a study, the
Florence Randomized Elective Stenting in Acute Coronary Oc-
clusions (FRESCO) trial, was performed in a relatively small
number of patients (n  150) undergoing primary angioplasty
using now obsolete first-generation stents, demonstrating not only
marked reductions in clinical and angiographic restenosis, but also
nonsignificant reductions toward reduced rates of mortality and
reinfarction (2).
Where we do agree with Massel is in our disdain for composite
end points. Although at times a necessary evil to allow realistic
sample sizes in randomized trials, they may obscure the forest for
the trees. Hierarchical rankings, unfortunately, introduce as many
new problems and vagaries as they solve. A balanced perspective
can usually be obtained through careful consideration of the
patient populations and methods, and by judicious examination of
all component end points. Finally, as important as it is to
understand beta error (realizing that real differences between
groups may not become statistically apparent with small sample
sizes), it is equally vital to recognize that small sample sizes can also
by chance suggest possible differences (or even large treatment
effects) where none exist.
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Characteristics of a Great Review
I found myself reacting to the Editor’s Page describing the
characteristics of an excellent manuscript peer review in a recent
issue of the Journal (1) with great surprise—surprise that these
characteristics had not previously been so carefully considered and
clearly communicated.
Dr. DeMaria states that “an excellent review is one that is
objective and constructive, one that avoids antagonism and points
out areas in which the article can be improved.” I would suggest
that this might be rephrased as, “One should write reviews one
would be happy to receive.” Far too many reviews are caustic and
derisive. They serve the medical literature poorly and can be
especially destructive to young researchers. It is not too much to
expect that a review be as dispassionately scientific as the work that
is being reviewed. The suggestions made by the editors of JACC
deserve widespread adoption.
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